AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 30, 2026, 8:10 AM ET Mobile-health Network Solutions Launches MaNaDr Health Operating Ecosystem Connecting AI-Powered Virtual and In-Person Care Headline · Source: company release
U.S. listed: $MNDRDigital healthcare and AI infrastructureExecution and funding risks

MNDR Stock Hub: Mobile-health Network Solutions News, Digital Healthcare and Infrastructure

Mobile-health Network Solutions is a company in transition. Its established identity is digital healthcare, associated with MaNaDr and Singapore operations. The newer narrative includes clinic software, AI-supported workflows, a Ghana venture and Malaysian data centers. A useful Hub must keep those businesses distinct rather than assume that every AI announcement validates the same earnings thesis. The FY2026 annual report shows $7.74 million revenue, $1.64 million gross profit and a $3.19 million net loss for the year ended June 30, 2026. Cash was $2.55 million at June 30; operating cash use was $1.53 million and investing cash use $4.26 million over the year. Financing inflows of $7.43 million supported liquidity. Going-concern uncertainty remains material. FY2026 annual report In April, the company disclosed a definitive securities purchase agreement for MYR500 million, approximately $126 million at the stated conversion, intended for Malaysian AI data-center construction. Funding is staged and closing conditions apply. The agreement anticipates substantial equity issuance and a 65% economic stake for the investor following full completion. Separate super-voting arrangements mean economic ownership and voting control must be assessed independently. In August and September, filings described remuneration awards involving millions of Class A shares and a new Class C allocation. Those developments make a stale vendor denominator particularly dangerous. A small historical float can coexist with substantial restricted issuance and potential future supply; neither tells the whole story alone. The case can improve if software adoption converts into recurring gross profit, the financing milestones close on disclosed terms, and updated statements give investors a coherent consolidated picture. It deteriorates if ambitious commitments consume resources without corresponding receipts, if dilution runs ahead of progress, or if healthcare compliance and execution remain weak. This Hub organizes those tests rather than assigning a price target unsupported by a dependable current capital structure.

Last updated: November 2, 2026Market reference: October 30, 2026 regular-session closeFinancial period: Year ended June 30, 2026; historical interim discussion: December 31, 2025Archive research: October 30, 2026
Full research report · PDF
Mobile-health Network Solutions ($MNDR), research as of October 30, 2026
15 pages covering The report separates the established digital-healthcare activities from clinic software, Ghana plans and proposed Malaysian data-center development. It follows conditional funding, staged commitments, regulatory history and share structure, preserving the annual financial update alongside the older interim discussion. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company milestone
Operating and funding milestones · undated

After the October 30 annual filing, monitor documented funding receipts, transaction closing and measurable paid software adoption. Project agreements are separate from completed construction, financing and revenue; no fixed next results day is stated. Primary source

Company-guided windows remain forecasts; completed events are dated separately from the next operating or financial disclosure.
Mobile-health Network Solutions MNDR daily stock chart
Daily chart $MNDR. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

MNDR stock at a glance

Close · October 30, 2026
$0.9773
Regular-session close; +3.97% versus $0.9400 on October 29. USD.
Revenue
$7,741,187
Year ended June 30, 2026; audited
Gross profit / gross margin
$1,642,784 / 21.2%
FY2026; margin calculated as gross profit / revenue
Net loss
$3,187,380
Year ended June 30, 2026
Cash and cash equivalents
$2,549,951
June 30, 2026; not October cash
Shareholders' equity
$9,888,927
June 30, 2026
FY2026 operating cash outflow
$1,527,685
Year ended June 30, 2026
Net financing inflow · FY2026
$7,432,975
Year ended June 30, 2026; separate from operating cash outflow.

Where Mobile-health Network Solutions stands now

Mobile-health Network Solutions is a company in transition. Its established identity is digital healthcare, associated with MaNaDr and Singapore operations. The newer narrative includes clinic software, AI-supported workflows, a Ghana venture and Malaysian data centers. A useful Hub must keep those businesses distinct rather than assume that every AI announcement validates the same earnings thesis. The FY2026 annual report shows $7.74 million revenue, $1.64 million gross profit and a $3.19 million net loss for the year ended June 30, 2026. Cash was $2.55 million at June 30; operating cash use was $1.53 million and investing cash use $4.26 million over the year. Financing inflows of $7.43 million supported liquidity. Going-concern uncertainty remains material. FY2026 annual report In April, the company disclosed a definitive securities purchase agreement for MYR500 million, approximately $126 million at the stated conversion, intended for Malaysian AI data-center construction. Funding is staged and closing conditions apply. The agreement anticipates substantial equity issuance and a 65% economic stake for the investor following full completion. Separate super-voting arrangements mean economic ownership and voting control must be assessed independently. In August and September, filings described remuneration awards involving millions of Class A shares and a new Class C allocation. Those developments make a stale vendor denominator particularly dangerous. A small historical float can coexist with substantial restricted issuance and potential future supply; neither tells the whole story alone. The case can improve if software adoption converts into recurring gross profit, the financing milestones close on disclosed terms, and updated statements give investors a coherent consolidated picture. It deteriorates if ambitious commitments consume resources without corresponding receipts, if dilution runs ahead of progress, or if healthcare compliance and execution remain weak. This Hub organizes those tests rather than assigning a price target unsupported by a dependable current capital structure.

Execution and funding. Contrary case. The financial base is small relative to the announced infrastructure ambitions. FY2026 revenue rose only 1.2%, the annual auditor highlighted substantial doubt about going concern, and June 30, 2026 cash was $2.55 million. Management’s plans had not alleviated that doubt. Share issuances, a large authorized capital envelope and super-voting stock complicate the relationship between corporate progress and the economics of public Class A shares. Prior action against MaNaDr Clinic is a material regulatory episode. The 2024 license revocation concerned that named clinic and its outpatient services, not every company-related platform or partner.

The constructive case

Constructive case. The first half of FY2026 showed better gross profitability and lower operating expenses than the comparable period. A software-oriented model could improve the economics of serving clinics if products attract paying users and support costs remain controlled. The Ghana agreement gives international expansion a more concrete contractual framework. The Malaysian project could create a second business if its funding, ownership and construction milestones are completed. These are different potential sources of value and require different evidence.

The cautious case

Contrary case. The financial base is small relative to the announced infrastructure ambitions. FY2026 revenue rose only 1.2%, the annual auditor highlighted substantial doubt about going concern, and June 30, 2026 cash was $2.55 million. Management’s plans had not alleviated that doubt. Share issuances, a large authorized capital envelope and super-voting stock complicate the relationship between corporate progress and the economics of public Class A shares. Prior action against MaNaDr Clinic is a material regulatory episode. The 2024 license revocation concerned that named clinic and its outpatient services, not every company-related platform or partner.

Latest Mobile-health Network Solutions news

Oct 30, 2026

FY2026 annual report: $7.74 million revenue and going-concern uncertainty

For the year ended June 30, 2026, MNDR reported revenue of $7,741,187, up 1.2% from $7,646,739; gross profit of $1,642,784; and a net loss of $3,187,380. Cash and equivalents were $2,549,951 at June 30, while operating activities used $1,527,685 over the year and investing activities used $4,264,455. Financing activities provided $7,432,975. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern, and Note 2 says management’s plans had not alleviated that doubt. These are June financial balances, not October cash. FY2026 Form 20-F

Oct 30, 2026

Mobile-health Network Solutions launches MaNaDr Health operating ecosystem connecting AI-powered virtual and in-person care

Mobile-health Network Solutions has launched the MaNaDr Health operating ecosystem. The ecosystem connects AI-powered virtual and in-person care.

Sep 25, 2026

September 25 filing; September 22 board decision — equity remuneration.

September 25 filing; September 22 board decision — equity remuneration. The board approved allotment and issuance of 1,980,000 Class A shares and 500,000 Class C shares for six directors/officers for FY2027 remuneration, subject to transfer restrictions to be set out in a deed of undertaking. Each Class C share carries ninety votes. SEC 6-K.

Sep 9, 2026

September 9 filings — officer share awards (Form 4).

September 9 filings — officer share awards (Form 4). Co-CEO Teoh Pui Pui reported 60,690 Class A and 27,534 Class B shares, Co-CEO and Chairman Siaw Tung Yeng 40,460 Class A and 18,357 Class B shares, and CFO Leong Aik Huat 9,906 Class A shares, all acquired on August 27, 2026 as awards (code A) at a reported $1.64. Form 4 Teoh · Form 4 Siaw · Form 4 Leong.

Aug 18, 2026

August 18 filing; August 17 board decision — personnel awards.

August 18 filing; August 17 board decision — personnel awards. The company reported approval of 1,120,000 Class A shares for 39 key personnel for FY2027 remuneration. This is relevant to the denominator and compensation analysis even where transfer restrictions limit immediate market supply. SEC 6-K.

Aug 12, 2026

August 12 filing; August 11 agreement — proposed minority clinic investment.

August 12 filing; August 11 agreement — proposed minority clinic investment. MNDR agreed to acquire 19% of Jurong Day & Night Clinic for $256,500, payable with 186,410 shares. Closing conditions, software deployment milestones and seller repurchase rights matter. The seller retains operating control; MNDR receives no board seat. SEC 6-K.

MNDR stock catalysts and company milestones

  • Operating and funding milestones · undated — After the October 30 annual filing, monitor documented funding receipts, transaction closing and measurable paid software adoption. Project agreements are separate from completed construction, financing and revenue; no fixed next results day is stated. Company guidance or announced event; timing qualifications retained

Primary source

What the company actually does

The starting point is the legal issuer, not the current market theme. Mobile-health Network Solutions is the Nasdaq-listed company, headquartered in Singapore, with MaNaDr-related healthcare activities described in its annual filing. Its ordinary shares, corporate subsidiaries, clinical service arrangements and technology products are not interchangeable legal objects. This matters because a license can belong to a specific clinic, an agreement can belong to a subsidiary, and a funding commitment can be earmarked for a particular project rather than available for general operations.

The annual report describes a healthcare model involving telemedicine services and the supporting platform. The newer Otter.SG proposition extends that technology into clinic operations, combining clinical and administrative workflows. Conceptually, this offers a path from individual consultations toward software revenue. But the economic proof would be visible in paid accounts, retention, contract duration, recurring revenue and gross profit after service costs. A broad description of a platform does not supply those measurements.

Primary source

Other financing proposals and the danger of adding headlines

The May filings describe two additional financing-related initiatives. The first is a nonbinding memorandum with Hector Capital concerning potential investment of up to $119 million to support possible majority acquisitions of BIMA and M&M Helix. The conditions include due diligence, definitive agreements, regulatory approval and independent valuation. Those qualifications are part of the investment proposition, not technical footnotes. May 4 SEC filing.

The second is a nonbinding memorandum with White Group to identify and facilitate a US-based private-equity fund that could invest up to $100 million for healthcare-technology initiatives. It is a facilitation framework, not evidence that White Group itself has funded the company. White Group was to present a fund candidate to the board within 60 days. The filing explicitly warns that definitive agreements or completed transactions are not assured. May 13 SEC filing.

Primary source

Merlintrader Health Score · $MNDR

1.65out of 5
Financial resources · 30%1.5

Old interim cash balance, historical cash consumption and conditional project funding

Catalysts · 30%2.0

Specific milestones are identifiable, but reliable completion dates and financial effects remain uncertain

Capital allocation · 20%1.0

Recent awards, multiple voting classes and an unreconciled current share denominator

Trading liquidity · 10%2.0

Public Nasdaq trading, but volatile price discovery and unreliable float fields limit confidence

Operating execution · 10%2.0

Real revenue and margin improvement, offset by losses, limited quantified software adoption and regulatory history

Assessed Original assessment date not stated; historical assessment, not rescored. Weighted calculation: 1.5×30% + 2.0×30% + 1.0×20% + 2.0×10% + 2.0×10% = 1.65. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • Contrary case. The financial base is small relative to the announced infrastructure ambitions. FY2026 revenue rose only 1.2%, the annual auditor highlighted substantial doubt about going concern, and June 30, 2026 cash was $2.55 million. Management’s plans had not alleviated that doubt. Share issuances, a large authorized capital envelope and super-voting stock complicate the relationship between corporate progress and the economics of public Class A shares. Prior action against MaNaDr Clinic is a material regulatory episode. The 2024 license revocation concerned that named clinic and its outpatient services, not every company-related platform or partner.
  • Company forecasts depend on execution and may change.
  • Financial balances retain their stated reporting date; later financing is separate.
  • Investment involves possible loss of part or all of the capital.

MNDR Stock FAQ: Mobile-health Network Solutions Questions Answered

What is the next catalyst for MNDR stock?

As of November 2, 2026, MNDR’s Malaysian data-center plan depended on funding, permits, construction and customer milestones. Its April 28 announcement targeted initial commercial operations in 2027, rather than a fixed near-term opening date. The October 30 annual report still described acquisition conditions pending at June 30. April 28 staged development plan. FY2026 acquisition disclosures.

How much revenue does MNDR make?

MNDR reported US$7.741 million of revenue and a US$3.187 million net loss for the fiscal year ended June 30, 2026. These are annual operating results in its October 30 filing, not the headline value of proposed infrastructure investments. FY2026 operating results.

How much cash does MNDR have, and is it enough?

MNDR had US$2.550 million in cash and equivalents at June 30, 2026, after using US$1.528 million in operations during the fiscal year. Its October 30 annual report states that management’s funding plans had not alleviated substantial doubt about continuing as a going concern. Balance sheet, cash flow and going-concern note.

What is the dilution risk for MNDR shareholders?

MNDR’s October 30, 2026 annual report describes substantial share awards after June 30 and ongoing equity-funding arrangements. September 22 awards alone covered 1,980,000 Class A and 500,000 Class C shares. Earlier August awards and acquisition shares also matter. The June balance-sheet share counts therefore are not a current market-capitalization denominator; Class C carries 90 votes per share. Share capital, remuneration and subsequent events.

When does MNDR report its next financial results?

MNDR filed its FY2026 annual results on October 30, 2026. As of November 2, 2026, it had not announced its next financial-results date. The fiscal year ended June 30; the annual release should not be mistaken for a U.S.-style quarterly timetable. October 30 annual results. Company announcements. Company events.

What does Mobile-health Network Solutions do?

Mobile-health Network Solutions operates the MaNaDr digital-health platform, connecting patients and healthcare providers through telehealth and related technology. Its October 30, 2026 annual report also describes planned AI infrastructure expansion. Its principal disclosed business is healthcare services and technology rather than developing investigational drugs. Business overview and expansion plans.

Has MNDR received the US$126 million investment for its 60 MW data-center project?

MNDR’s April 28, 2026 announcement described a planned MYR500 million, approximately US$126 million, investment in milestone-linked tranches, not an immediate full cash payment. The proposed 60 MW Malaysian campus would be developed in phases, with funding linked to permits, construction and commercial milestones. Those planned funds are not the June 30 cash balance reported in the October 30 annual filing. April 28 company announcement. Reported cash and acquisition conditions.

Did MNDR’s June reverse stock split improve its finances?

MNDR’s June 2026 consolidation combined six ordinary shares into one, with split-adjusted Nasdaq trading beginning June 29. The split changed share quantities and per-share presentation; it did not itself generate cash, revenue or new operating assets. Subsequent share awards and financing transactions affect ownership separately. Share consolidation and equity disclosures.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $MNDR or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Healthcare and technology companies face clinical, regulatory, commercial, execution and financing risks. Product development and commercial agreements do not guarantee approval, profitable sales or cash collection. Additional borrowing or equity issuance can increase obligations or dilute shareholders. Investors can lose part or all of their capital. Every reader is responsible for their own decisions.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.